Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Galderma Group News

Aktie
WKN:  A407X6 ISIN:  CH1335392721 US-Symbol:  GDERF Branche:  Pharmazeutika Land:  Schweiz
156,85 CHF
+5,10 CHF
+3,36%
170,59 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
41,47 Mrd. €
Streubesitz
16,67%
KGV
103,51
Dividende
0,16 EUR
Dividendenrendite
0,092%
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,92: MM4UH9
Werbung

Galderma Group News

16.04.26 - Businesswire
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a ...
09.04.26 - Businesswire
Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause
Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra – the first proven regenerative ...
07.04.26 - Businesswire
Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, ...
28.03.26 - Businesswire
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-​to-severe ...
24.03.26 - Businesswire
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of ...
23.03.26 - Businesswire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in ...
20.03.26 - Businesswire
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held ...
17.03.26 - Businesswire
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data ...
11.03.26 - Businesswire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total ...
11.03.26 - Businesswire
Galderma Completes Successful Placement of EUR 500 Million Eurobond
Galderma Group AG (SWX:GALD):
09.03.26 - Businesswire
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-​recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant ...
05.03.26 - Businesswire
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025.
27.02.26 - Businesswire
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
Galderma (SIX: GALD) today announced new data from the OLYMPIA open-​label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-​to-severe ...
12.02.26 - Businesswire
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra , a unique program designed to capture the clinical impact of Sculptra ® across ...
11.02.26 - Businesswire
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid ...
02.02.26 - Businesswire
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-​to-severe ...
30.01.26 - Businesswire
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-​menopausal women from nine countries exploring the impact of menopause on the skin at the ...
29.01.26 - Businesswire
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. ...
22.01.26 - Businesswire
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio
Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator ...
21.01.26 - Businesswire
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the ...

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »